Presentations review clinical results of 10
kHz Therapy™ for the treatment of chronic back
and leg pain, non-surgical back pain (NSBP), and painful
diabetic neuropathy (PDN)
REDWOOD
CITY, Calif., Jan. 17,
2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced a series of data presentations supporting the use of the
company's HFX™ 10 kHz Therapy for patients with chronic pain.
Results will be presented at the 2024 North American
Neuromodulation Society (NANS) Annual Meeting held from
January 18-21, 2024 at Caesars Palace
Las Vegas.
A total of 25 scientific abstracts reviewing clinical results
for 10 kHz Therapy™, including four podium presentations and 21
posters, will be presented at the conference. Nevro will also host
a Lunch Symposium showcasing the benefits of the company's
AI-enabled HFX iQ™ system in a presentation titled "HFX iQ
Accelerating Outcomes with Real-Time, Proactive Care" on
Saturday, January 20, from 12:00 –
1:00 p.m. PST, in the Augustus
Ballroom. The company will also unveil its new sacroiliac (SI)
joint fusion portfolio at exhibit booth #0238.
"Our strong presence at NANS underscores Nevro's dedication to
continuously improving the chronic pain field and providing the
best possible pain management solutions to patients," said
Kevin Thornal, Nevro's CEO and
President. "The growing body of clinical evidence from our 25
scientific abstracts displays the substantial benefits of 10 kHz
Therapy and we look forward to continuing to treat underserved
patient populations suffering from debilitating chronic pain."
Key presentations are highlighted below (all times PST):
Painful Diabetic Neuropathy (PDN) and 10 kHz Therapy™
Main Session: "Scientific Advances in
Neuromodulation Session 1"
- Saturday,
January 20, 2024, 10:30 - 12:00
p.m., Emperors Ballroom
Concurrent Session: "10 kHz SCS Treatment of Painful
Diabetic Neuropathy: Results Combining Dermatomal Dysesthesias and
Lower Limb Sensory Assessments," presented by David Caraway, M.D., Ph.D., Senior Vice
President and Chief Medical Officer, Nevro
- Saturday,
January 20, 2024, 10:40 - 10:48
a.m., Emperors Ballroom
Concurrent Session: "Quantifying the Neural Response
to Kilohertz Spinal Cord Stimulation Using Calcium-Sensitive
Imaging," presented by Dongchul Lee,
Director of Theoretical Research, Nevro
- Saturday,
January 20, 2024, 11:12 - 11:20
a.m., Emperors Ballroom
Main Session: "The Future is NOW: Late Breaking Science
Updates"
- Saturday,
January 20, 2024, 1:30 - 3:30
p.m., Octavius Ballroom
Plenary Session: "10 kHz SCS Treatment of Painful
Diabetic Neuropathy: Significant Reductions in HbA1c, Weight, and
Pain," presented by Johnathan Goree,
M.D., University of Arkansas for
Medical Sciences
- Saturday,
January 20, 2024, 2:15 - 2:23
p.m., Octavius Ballroom
Non-Surgical Back Pain (NSBP)
Main Session: "Neuromodulation and Athletics.
Parallels and Lesson"
- Saturday,
January 20, 2024, 4:00 - 5:30
p.m., Neapolitan Ballroom
Concurrent Session: "Comparing 10 kHz Spinal Cord
Stimulation Efficacy in Persistent Spinal Pain with and without
Previous Spine Surgery," presented by Leonardo Kapural, M.D.,
Carolinas Pain Institute
- Saturday,
January 20, 2024, 5:14 - 5:22
p.m., Neapolitan Ballroom
For more information, please visit
https://conference.neuromodulation.org/.
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes the SenzaR SCS
system and support services for the treatment of chronic pain of
the trunk and limb and painful diabetic neuropathy. Nevro recently
added a minimally invasive treatment option for patients suffering
from chronic sacroiliac joint ("SI joint") pain and now provides
the most comprehensive portfolio of products in the SI joint fusion
space, designed to meet the preferences of physicians and varying
patient needs in order to improve outcomes and quality of life for
patients.
Senza®, Senza II®, Senza OmniaR, and HFX iQ™ are the
only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.
Nevro's unique support services provide every patient with HFX
Coach™ support throughout their pain relief journey and every
physician with HFX Cloud™ insights for enhanced patient and
practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, X
(Twitter), Facebook, and Instagram.
Investors and Media:
Angie McCabe
Vice President, Investor Relations & Corporate
Communications
angeline.mccabe@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-to-highlight-25-scientific-abstracts-at-2024-north-american-neuromodulation-society-nans-annual-meeting-302037371.html
SOURCE Nevro Corp.